Merck Strengthens Research Cooperation With Israel
Initiation of the Merck Serono Israel Bioincubator Program
The incubator program is designed to accelerate the successful development of entrepreneurial start-up companies and will offer both seed financing and the opportunity of using a dedicated part of Merck Serono’s Israeli research and development center, Interlab, for their own research. Over a seven-year time span, Merck Serono will invest a total of EUR 10 million. In parallel Merck Chemicals will initiate a program for start-up companies in the area of high-tech and life science materials. Merck Chemicals will allocate as much as EUR 3 million within the next three years in this program.
Israeli companies will be selected based on their potential for developing innovative technologies aligned with the company’s strategy, which could enable the discovery and development of new products. Merck’s incubator program encompasses the fields of pharmaceuticals, life sciences and performance materials.
“We hope this new incubator program will further strengthen our research cooperations here because Israel is one of the top countries for scientific innovation and start-up companies in the fields of biopharmaceuticals and high-tech materials,” Kley said.
Merck has participated since 2007 in the Global Enterprise Collaboration Framework Program of the of Israeli Ministry of Industry, Trade and Labour, which was set up to grant Israeli partners several benefits including dedicated technical, marketing and sales support in worldwide market places as well as access to business development and application technology resources. A new call for proposals for this program was provided to the Ministry today.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.